01—Abstract
Summary
Summary of the 10-K filed February 19, 2015. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company's 2014 10-K filing reveals a challenging year primarily marked by significant revenue decline due to patent expirations for key products like Cymbalta and Evista.
This led to a substantial decrease in net income and earnings per share compared to the previous year. Despite these headwinds, the company continued to invest heavily in research and development, focusing on core areas like diabetes and oncology. A major strategic move highlighted is the pending acquisition of Novartis Animal Health, expected to close in early 2015, which aims to significantly bolster Elanco's position in the animal health market.
The company is navigating a complex operating environment characterized by intense competition from generic and biosimilar manufacturers, increasing pricing and reimbursement pressures from payers, and ongoing patent challenges. Lilly is actively managing its patent portfolio and investing in a robust late-stage pipeline to offset upcoming patent cliffs. The financial performance in 2014 was also impacted by various charges related to restructuring, asset impairments, and a one-time accelerated expense recognition for the U.S. Branded Prescription Drug Fee.
02—Key points
Key Highlights
- Significant revenue and net income decline in 2014 primarily due to patent expiries of Cymbalta and Evista, leading to increased generic competition.
- Heavy investment in R&D ($4.73 billion in 2014) continues, with a focus on diabetes, oncology, neuroscience, immunology, and pain, showcasing a robust pipeline with multiple late-stage candidates.
- Completion of the acquisition of Novartis Animal Health for approximately $5.4 billion is a major strategic initiative expected to strengthen the Elanco division.
- The company is actively engaged in patent litigation and administrative proceedings for key products like Alimta and Effient, highlighting the importance of intellectual property protection.
- Increased pricing and reimbursement pressures from managed care organizations and government entities globally are noted as significant ongoing challenges.
- Year-over-year revenue decreased by 15%, driven by a 29% drop in U.S. revenue, while international revenue saw a modest 3% increase.
- The company repurchased $800 million of its stock in 2014 as part of its ongoing share repurchase program.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2014filed February 19, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| Revenue | $19.62B$23.11B | −15.1% |
| Cost of Revenue | $4.93B$4.91B | +0.5% |
| Gross Profit | $14.68B$18.20B | −19.3% |
| R&D Expenses | $4.73B$5.53B | −14.4% |
| SG&A Expenses | $6.62B$7.13B | −7.1% |
| Interest Expense | $148.80M$160.10M | −7.1% |
| Net Income | $2.39B$4.68B | −49.0% |
| EPS (Basic) | $2.23$4.33 | −48.5% |
| EPS (Diluted) | $2.23$4.32 | −48.4% |
| Shares Outstanding (Basic) | 1.07B1.08B | −1.0% |
| Shares Outstanding (Diluted) | 1.07B1.08B | −1.0% |
05—Questions
Frequently Asked Questions
What were the main drivers of Eli Lilly's financial performance in 2014?
The primary drivers of Eli Lilly's financial performance in 2014 were the loss of U.S. patent exclusivity for Cymbalta and Evista, which led to a significant decline in revenue from these products due to generic competition. This, combined with various charges related to restructuring and asset impairments, resulted in lower net income and earnings per share compared to 2013.
How is Eli Lilly addressing the impact of patent expirations?
Eli Lilly is addressing patent expirations by heavily investing in research and development to build a strong pipeline of new drugs. The company has a significant number of late-stage drug candidates across various therapeutic areas and is also focused on defending its existing intellectual property through patent litigation and administrative proceedings.
What is the significance of the Novartis Animal Health acquisition for Eli Lilly?
The acquisition of Novartis Animal Health for approximately $5.4 billion, completed in early 2015, is a major strategic move expected to significantly enhance Elanco, Eli Lilly's animal health division. It aims to expand Elanco's product portfolio, broaden its global commercial presence, and strengthen its manufacturing and R&D capabilities, particularly in companion animal and swine markets.
What are the key risks and challenges facing Eli Lilly as outlined in the filing?
Key risks and challenges include the high cost and uncertainty of pharmaceutical R&D, intense competition from other pharmaceutical companies and generic/biosimilar manufacturers, the impact of patent expirations on revenue, potential invalidation or weakening of intellectual property rights, increasing government price controls and reimbursement pressures, regulatory compliance, manufacturing disruptions, and the successful integration of acquired businesses like Novartis Animal Health.
06—Continue